



COLLEGE of AMERICAN
PATHOLOGISTS
Laboratory Quality Solutions

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2022

Participant Summary

This document is available online in e-LAB Solutions Suite.

© 2022 College of American Pathologists. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

2022 PIP/PIPW-B PARTICIPANT SUMMARY

Program Update

This report summarizes the diagnostic responses for set B of the 2022 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Aaron Auerbach, MD FCAP, Chair
Raul Gonzalez, MD FCAP, Vice-Chair

Oyedele A. Adeyi, MBBS, FCAP
Nadine S. Aguilera, MD, FCAP
Vijayalakshmi Ananthanarayanan, MD, MBBS FCAP
Phyu P. Aung, MD, PhD, FCAP
Lamé Balikani, MD, MPH
Deborah Ann Belchis, MD, FCAP
Miriam Conces, MD, FCAP
Kossivi Dantey, MD, FCAP
Megan B. Fitzpatrick, MD, FCAP
Juan C. Hernandez-Prera, MD, FCAP

Mojgan Hosseini, MD, FCAP
Taylor McAneney Jenkins, MD, FCAP
Xiaoyin Jiang, MD, FCAP
Mitra Mehrad, MD, FCAP
Vinita Parkash, MD, FCAP
Anwar Sultana Sabiha Raza, MD, FCAP
Nicole D. Riddle, MD, FCAP
Lauren Schwartz, MD, FCAP
Robert A. Schwartz, MD, FCAP
Steven S. Shen, MD, PhD, FCAP
Sabrina C. Sopha, MD, FCAP

Diagnosis					
Code	Diagnosis	PIP Participants	No.	PIPW Participants	No.
5774	Central atypical cartilaginous tumor	82	1.5	30	8.0
5775	Central chondrosarcoma, grade 2	5226	96.2	257	69.0
1194	Chondroblastic osteosarcoma	41	0.8	9	2.4
2698	Chondromyxoid fibroma	10	0.2	7	1.9
5776	Melanoma	71	1.3	70	18.7

Technical Quality of Slide					
Rating	Glass Slide Evaluation	PIP Participants	No.	%	
001	Excellent	2020	42.7		
002		951	19.5		
003	Satisfactory	1479	30.4		
004		303	6.2		
005	Unsatisfactory	59	1.2		

Diagnosis					
Code	Diagnosis	PIP Participants	No.	PIPW Participants	No.
5779	Classic Hodgkin lymphoma, nodular sclerosis subtype	3	0.1	0	0.0
1678	Graves disease	17	0.3	1	0.3
5777	IgG4-related thyroiditis	5405	99.5	356	99.4
5778	Papillary thyroid carcinoma, diffuse sclerosing variant	5	0.1	1	0.3

Technical Quality of Slide					
Rating	Glass Slide Evaluation	PIP Participants	No.	%	
001	Excellent	2368	49.5		
002		1000	20.9		
003	Satisfactory	1295	27.1		
004		99	2.1		
005	Unsatisfactory	18	0.4		

Case # 2022-13

Diagnosis					
		PIP Participants		PIPW Participants	
Code	Diagnosis	No.	%	No.	%
2081	Adult granulosa cell tumor	133	2.5	81	23.3
1712	Carcinoid tumor	1	<0.1	1	0.3
5780	Endometrioid carcinoma with sex cord-like features	4	0.1	2	0.6
1958	Fibrosarcoma	0	0.0	0	0.0
2496	Sertoli-Leydig cell tumor (moderately to poorly differentiated)	5292	97.5	263	75.8

Technical Quality of Slide

		PIP Participants	
Rating	Glass Slide Evaluation	No.	%
001	Excellent	2325	48.8
002		1030	21.7
003	Satisfactory	1262	26.6
004		120	2.5
005	Unsatisfactory	17	0.4

Case # 2022-14

Diagnosis					
		PIP Participants		PIPW Participants	
Code	Diagnosis	No.	%	No.	%
1547	Acinic cell carcinoma	5307	97.7	227	66.4
1721	Adenoid cystic carcinoma	29	0.5	22	6.4
5781	Carcinoma ex pleomorphic adenoma	8	0.2	18	5.3
1881	Mucoepidermoid carcinoma	39	0.7	48	14.0
5660	Secretory carcinoma	48	0.9	27	7.9

Technical Quality of Slide

		PIP Participants	
Rating	Glass Slide Evaluation	No.	%
001	Excellent	2442	51.5
002		925	19.5
003	Satisfactory	1233	26.0
004		123	2.6
005	Unsatisfactory	17	0.4

Case # 2022-15

Diagnosis		PIP Participants		PIPW Participants	
Code	Diagnosis	No.	%	No.	%
2963	Metastatic clear cell renal cell carcinoma	9	0.2	3	0.9
1305	Pancreatic ductal adenocarcinoma	6	0.1	3	0.9
1183	Serous cystadenocarcinoma	349	6.4	15	4.5
1982	Serous cystadenoma	5052	93.1	312	93.1
1736	Well-differentiated neuroendocrine tumor, clear cell variant	12	0.2	2	0.6

Technical Quality of Slide		PIP Participants		PIPW Participants	
Rating	Glass Slide Evaluation	No.	%	No.	%
001	Excellent	2317	49.6		
002		932	20.0		
003	Satisfactory	1254	26.8		
004		140	3.0		
005	Unsatisfactory	29	0.6		

Case # 2022-16

Diagnosis		PIP Participants		PIPW Participants	
Code	Diagnosis	No.	%	No.	%
1770	Adult cystic nephroma	5339	98.3	232	69.9
2835	Autosomal dominant polycystic kidney disease	19	0.4	18	5.4
1665	Clear cell renal cell carcinoma	1	<0.1	4	1.2
5782	Multilocular cystic neoplasm of low malignant potential	66	1.2	73	22.0
2344	Tubulocystic renal cell carcinoma	5	0.1	5	1.5

Technical Quality of Slide		PIP Participants		PIPW Participants	
Rating	Glass Slide Evaluation	No.	%	No.	%
001	Excellent	2312	49.7		
002		973	20.9		
003	Satisfactory	1247	26.8		
004		108	2.3		
005	Unsatisfactory	11	0.2		

Case # 2022-17

Diagnosis

(5783) Nonseminomatous mixed germ cell tumor

Code	Diagnosis	PIP Participants No.	PIP Participants %	PIPW Participants No.	PIPW Participants %
1060	Choriocarcinoma	7	0.1	4	1.2
5783	Nonseminomatous mixed germ cell tumor	5394	99.3	304	92.5
2383	Seminoma	9	0.2	8	2.4
2075	Sex cord-stromal tumor, mixed	18	0.3	8	2.4
5784	Teratoma, post-pubertal type	2	<0.1	5	1.5

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants No.	PIP Participants %
001	Excellent	2342	50.4
002		945	20.3
003	Satisfactory	1250	26.9
004		103	2.2
005	Unsatisfactory	11	0.2

Case # 2022-18

Diagnosis

(1646) Leiomyoma

Code	Diagnosis	PIP Participants No.	PIP Participants %	PIPW Participants No.	PIPW Participants %
5785	Fumarate hydratase-deficient leiomyoma	58	1.1	42	12.9
1646	Leiomyoma	5325	98.1	262	80.7
2389	Leiomyosarcoma	18	0.3	0	0.0
5786	Low-grade endometrial stromal sarcoma	10	0.2	2	0.6
1896	Smooth muscle tumor of uncertain malignant potential	17	0.3	19	5.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants No.	PIP Participants %
001	Excellent	2209	47.7
002		926	20.0
003	Satisfactory	1290	27.9
004		180	3.9
005	Unsatisfactory	25	0.5

Diagnosis					
(5789) Smoking-related interstitial fibrosis					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5787	Fibrotic nonspecific interstitial pneumonia	119	2.2	52	16.2
5788	Pulmonary Langerhans cell histiocytosis	13	0.2	14	4.4
2135	Respiratory bronchiolitis interstitial lung disease	70	1.3	44	13.7
5789	Smoking-related interstitial fibrosis	5157	95.3	176	54.8
2266	Usual interstitial pneumonia	52	1.0	35	10.9

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants		PIPW Participants	
		No.	%	No.	%
001	Excellent	2159	47.3		
002		944	20.7		
003	Satisfactory	1299	28.5		
004		114	2.5		
005	Unsatisfactory	47	1.0		

Diagnosis					
(1075) Intramuscular myxoma					
Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2600	Deep (aggressive) angiomyxoma	26	0.5	18	5.6
1075	Intramuscular myxoma	5330	98.4	260	81.3
2440	Low-grade fibromyxoid sarcoma	30	0.6	19	5.9
1058	Myxofibrosarcoma	10	0.2	11	3.4
1700	Myxoid liposarcoma	15	0.3	12	3.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants		PIPW Participants	
		No.	%	No.	%
001	Excellent	2185	48.0		
002		885	19.5		
003	Satisfactory	1287	28.3		
004		139	3.1		
005	Unsatisfactory	55	1.1		



This concludes the report.



**COLLEGE of AMERICAN
PATHOLOGISTS**
Laboratory Quality Solutions

325 Waukegan Road
Northfield, IL 60093-2750
800-323-4040
847-832-7000 (Country code: 001)